April 12, 2007 -- MedImmune engaged Goldman Sachs to find a merger partner; the National Kidney Foundation reduced its target hemoglobin levels for patients on dialysis, affecting drugs from Amgen and Johnson and Johnson; Indevus set the exchange ratio for its stock-based takeover of Valera; Idenix said that valopicitabine failed two Phase IIb trials for hepatitis C; Affymax reported Hematide was as effective as EPO; DOR BioPharma rebuffed a buyout bid from Cell Therapeutics; Novartis sold its Gerber baby food business to Nestle for $5.5 billion in cash; and Coley Pharma licensed its VaxImmune vaccine adjuvant to Merck. The Nasdaq Biotech Index rose 1.7%. More details...
